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Although preterm birth is associated with respiratory morbidity in childhood, the role of fam-
ily history of atopy and whether appropriate treatment has been instituted is unclear. Thus
we assessed (i) the prevalence of respiratory symptoms, particularly wheezing, in child-
hood; (ii) evaluated the role of family history of atopy and mode of delivery, and (iii) docu-
mented the drug usage, all in preterm-born children compared to term-born control children.
Methods
We conducted a cross-sectional population-based questionnaire study of 1–10 year-old
preterm-born children (n = 13,361) and matched term-born controls (13,361). Data (n =
7,149) was analysed by gestational groups (24–32 weeks, 33–34 weeks, 35–36 weeks and
37–43 weeks) and by age, <5 years old or ≥ 5 years.
Main Results
Preterm born children aged <5 years (n = 2,111, term n = 1,402) had higher rates of
wheeze-ever [odds ratio: 2.7 (95% confidence intervals 2.2, 3.3); 1.8 (1.5, 2.2); 1.5 (1.3, 1.8)
respectively for the 24–32 weeks, 33–34 weeks, 35–36 weeks groups compared to term].
Similarly for the ≥5 year age group (n = 2,083, term n = 1,456) wheezing increased with
increasing prematurity [odds ratios 3.3 (2.7, 4.1), 1.8 (1.5, 2.3) and 1.6 (1.3, 1.9) for the
three preterm groups compared to term]. At both age groups, inhaler usage was greater in
the lowest preterm group but prematurity-associated wheeze was independent of a family
history of atopy.
Conclusions
Increasing prematurity was associated with increased respiratory symptoms, which were
independent of a family history of atopy. Use of bronchodilators was also increased in the
preterm groups but its efficacy needs careful evaluation.
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Introduction
Preterm birth, defined as birth before 37 weeks’ of gestation, has a major impact on health ser-
vices across the world, with preterm birth rates varying from 7% in England and Wales to
11.4% in the USA [1, 2]. Children born preterm are known to have a greater prevalence of neu-
rodevelopmental and respiratory problems compared to those born at term [3, 4]. Improved
neonatal care has led to greater survival of preterm-born infants, thus the long-term outcomes
including respiratory morbidity have become increasingly important [5, 6]. Of note preterm-
born children have been shown to be at increased risk of developing wheeze-related disorders
[7]; however, the exact nature of the prematurity-associated wheeze has been poorly described,
particularly its relationship to atopy and use of inhaler medication. In many studies, prematu-
rity-associated wheezing is labeled as ‘asthma’ but the greater prevalence of respiratory symp-
toms in preterm-born children than term-born equivalents, suggests possible alternative
mechanisms that need identifying. The resulting respiratory morbidity from long-term survival
of preterm birth may require a new diagnostic label, which may have altered rates of atopy and
different responses to existing inhaled treatments traditionally used in asthma. Some of the
outcome data to date has been based on identifying preterm-born subjects from medication
use in population-based registries, which has a risk of selection bias and thus potential over
diagnosis of asthma and therefore will identify higher rates of treatment [8]. In contrast, other
studies report under-treatment of airway obstruction associated with extremes of prematurity
[4, 9]. So it is clearly important to assess in a large cohort study the rate of inhaler medication
use by children with prematurity-associated wheeze.
Preterm-born children are at risk of developing deficits in percentage forced expiratory vol-
ume in one second (%FEV1) and have increased admissions to hospital for respiratory related
illnesses when compared to term-born children [5, 6, 10]. Both of these studies, Kotecha et al &
Paranjothy et al [5, 10], included children born moderate, late and very preterm including
those who developed chronic lung disease of prematurity (CLD), who have previously been
shown to have the highest risk of developing respiratory morbidity in childhood [11, 12]. In a
recent publication using the cohort from the current study, we assessed the independent effects
of early term (37 to 38 weeks of gestation), atopy and delivery by caesarian sections in future
development of wheezing when compared to full term-born children (39 to 41 weeks of gesta-
tion) [13]. However, Astle et al did not show a difference for risk of developing asthma in
young children born preterm with CLD compared to children born preterm without CLD [14].
Although Rosas-Salazar et al reported preterm birth was strongly associated with atopic
asthma, in a highly selected cohort of Puerto Rican children [15]. Therefore, it is important to
establish the characteristics of preterm-born children with and without CLD, who are at
increased risk of respiratory symptoms throughout childhood and to what extent these symp-
toms are related to a family history of atopy and mode of delivery. Furthermore, it is important
to establish whether children born preterm with respiratory symptoms are receiving appropri-
ate treatment.
The main study hypothesis was that children born preterm have increased respiratory
symptoms; have increased health care utilization and are treated more frequently with inhaler
medication when compared to term-born (37 to 42 weeks of gestation) children. Specifically
we have quantified the association between gestational age at birth and subsequent respiratory-
associated symptoms in preschool (<5 years of age) and school-aged (≥5 years of age) children.
We also evaluated the role of a family history of atopy and mode of delivery in the reporting of
prematurity-associated wheeze and documented drug usage in preterm-born children classi-
fied by gestational groups comparing all the results from the preterm group to the term group.
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Methods
Study Population
We conducted a cross-sectional population study of children born preterm between 1st January
2003 and 31st December 2011. During this period there were 305,894 live births inWales of
which 22,383 were born preterm (<37 weeks’ gestation). We studied all preterm-survivors born
in 2003, 2005 and 2007 thus were aged between 5 and 10 years of age in 2013 (n = 6,406), and
those born between 2009 to 2011 thus were aged less than five years of age in 2013 (n = 6,955). In
total 13,361 preterm-born children together with an equivalent number of term-born control
subjects born on the same day, gender and locality (n = 13,361) were invited to take part. All the
subjects were identified from the NHSWelsh Informatics Service (NWIS), which collates data
from health databases inWales including Patient Episode Database for Wales (PEDW, hospital
admissions), National Community Child Health Database (NCCHD, birth registration data) and
Welsh Demographics Service (WDS, social demographics). The South East Wales Research Eth-
ics Committee approved the study. The parents/guardians of the children, by virtue of complet-
ing and returning the questionnaires, consented to participate.
Survey
Questionnaires were mailed in April 2013 to the parents of the 26,722 subjects with a reminder
mailed to non-responders in June 2013. Children aged five years or less were sent the validated
Liverpool Respiratory Symptom Questionnaire (LRSQ) [16] and a modified International
Study of Asthma and Allergies in Children (ISAAC) questionnaire was mailed to children aged
five years or older [9, 17]. The ISAAC questionnaire was modified by including questions relat-
ing to respiratory symptoms and the LRSQ was a questionnaire designed to assess respiratory
symptoms in young children, having been validated in patients with cystic fibrosis[18]. All
returned questionnaires were scanned, validated, checked for accuracy and stored in a secure
database (Remark Office OMR 8, Gravic, Philadelphia, USA). Additional data, including gesta-
tional age at birth, birth weight, mode of delivery, hospital of birth, the family’s ethnicity and
Welsh Index of Multiple Deprivation score (WIMD)[19], a measure of social deprivation
based on income, employment, education and health with a range of 1 (most deprived) to 1909
(least deprived), were obtained from NWIS.
Exposure
The main exposure of interest, gestational age at birth, was based on antenatal ultrasound
scans and maternal reporting and recorded in completed weeks of gestation. It was categorized
into four groups: 24 to 32 weeks (very preterm), 33 to 34 weeks (moderate preterm), 35 to 36
weeks (late preterm) and 37 to 43 weeks (term controls) as in our previous report [11]. Birth
weight was used as a continuous variable and z-scores were calculated using the LMS Growth
program (Medical Research Council, UK)[20], which takes into account gestational age and
gender. Intrauterine growth restriction (IUGR) was defined as<10th centile for birth weight
(after correcting for gender and gestation) and was compared to children with birth weights
between 20-80th centile. Participants with birth weights outside ±3.5 SDs or with unknown ges-
tational age were excluded. Of the 7,149 responders, 97 children were excluded due to implau-
sible birth weight or gestational age at birth.
Outcomes
Respiratory outcomes were based on questionnaire responses and included wheeze-ever, recent
wheezing (mild wheeze–a few days per week and severe–almost every day per week), other
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respiratory symptoms (cough, shortness of breath and/or coryzal symptoms), use of inhalers
(bronchodilators and corticosteroids), hospital admissions for chest-related problems in the
last twelve months, doctor diagnosed asthma and family history of atopy, which was based on
parental reporting of first degree relatives having a history of asthma, eczema and hay fever.
Diagnosis of CLD was based on parental reporting and checked with the data on the hospital
discharge notification. CLD, which was confined to the children born at32 weeks of gestation
as need for supplemental oxygen until at least 36 weeks of corrected gestational age [21, 22].
Parents were also asked if their child had any breathing problems and responded in a free text
box. Missing questionnaire responses were recoded as “no” for analysis.
Statistical analysis
Descriptive analyses were used to summarize the characteristics of all responders, matched case-
control responders and of all non-responders. Characteristics included age, gender, gestational
age, birth weight, WIMD score, maternal age, maternal smoking during pregnancy, mode of
delivery and IUGR. For the characteristics of the responders, we compared results between the
gestational groups using appropriate statistical tests (gestational age and birth weight were com-
pared by T-tests; WIMD score by Mann-Whitney U-test; and gender, mode of delivery, IUGR by
chi-square) after testing for normality by assessing distribution of frequencies and by performing
normal probability plots. Since the response rates were greater amongst the preterm group than
the term group, we performed sensitivity analyses by comparing wheezing rates between
matched preterm- and term-born children. Because of ethical arrangements, we only had access
to identifiable data for responders thus the term-borns were matched with a date of birth within
5 days of the preterm-subjects and with same locality and gender.
The prevalence rates were calculated as a percentage of the study population for each gesta-
tional group. The prevalence rates of respiratory symptoms, inhaler treatment, and hospital
admissions are reported according to gestational groups with odds ratio to measure the effect
size between groups. Separate univariate analyses by ANOVA were constructed for children
less than five years-of-age and those five years-of-age and older. Further univariate analyses
using ANOVA were conducted to identify risk factors that were associated with wheezing;
those statistically significant (p<0.05) were included in multivariable logistic regression analy-
sis for wheezing. Two generalized linear models of multivariable analyses were performed: the
first included all significant risk factors and the second included only family history of atopy.
Confounding and significant risk factors included in the generalized linear modeling were gen-
der, family history (FH) of atopy, maternal smoking during pregnancy, mode of delivery,
maternal history of asthma, breastfeeding at birth, current maternal smoking, social status, eth-
nicity, and other family member smoking. Adjusted odds ratios were calculated.
A sub-group analysis of wheezers only was performed, by comparing preterm- and term-
born wheezers. Univariate analyses using ANOVA were conducted to identify risk factors asso-
ciated with prematurity-associated wheezing. A separate univariate analysis by ANOVA was
performed to assess the influence of family history of atopy on wheezing preterm-born chil-
dren receiving inhaler treatment compared to wheezing term-born children on inhaler treat-
ment. Analyses were also performed to assess the differences in prevalence of wheezing and
inhaler treatment between preterm-born children with and without a family history of atopy
and term-born children with and without a family history of atopy. Finally a sub-group analy-
sis of the very preterm group was performed to assess the differences in prevalence of wheezing
and inhaler treatment between children with CLD and those without CLD. The statistical anal-
yses were performed using PAWS (version 18.0, SPSS Inc, Chicago, IL; US). p<0.05 was con-
sidered significant.
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Results
Participant characteristics
There were 7,149 (26.7%) responses with 4,284 (60%) from preterm-born and 2,865 (40%)
from term-born children (Fig 1). The characteristics of participants are shown in Tables 1 and
2 and comparisons to non-responders are shown in Tables A and B in S1 File. When compar-
ing the different characteristics of the descriptive analysis of included preterm-born children to
term-born controls using appropriate parametric or non-parametric tests, there were no signif-
icant differences for gender, age of child or maternal age at time of delivery. However, a trend
was noted for higher antenatal maternal smoking rates, greater delivery rates by caesarean sec-
tion and lower WIMD ranks in the preterm-born groups when compared to the term group.
There were 1,260 pairs of matched preterm- and term-born responders (total 2,520). The char-
acteristics were similar between the matched responders and all responders (Tables F and G in
S1 File).
Risk factors
Lower gestational age at birth, male gender, maternal smoking during pregnancy, current
maternal smoking, other family member current smoking, maternal history of asthma, delivery
by caesarean section (CS), family history of atopy, lower WIMD rank, and ethnicity were all,
individually, significantly associated with increased rates of wheezing for both age groups
(p<0.05). These risk factors were all included as in the multivariable analysis of wheezing
symptoms (Tables 3 and 4). Influence of CLD was analysed separately as it was confined to the
very preterm group (see below).
Prevalence
The prevalence of wheeze-ever in children less than five years-of-age was 64.7%, 55.5%, 51.4%
and 40.7% in the very preterm, moderate, late preterm and term groups respectively with odds
ratios of 2.67 (95%CI 2.2, 3.3), 1.82 (95%CI 1.5, 2.2) and 1.54 (95%CI 1.3, 1.8) respectively
(Table 3). Slightly higher odds ratios were noted for recent wheeze (over the last three months),
severity of wheezing, use of inhaler medication including corticosteroids and admission to hos-
pital over the last 12 months for a respiratory illness. Family history of atopy showed a preva-
lence of 26.1% in the very preterm group, 24% in the moderate preterm group, 31.4% in the
late preterm group and 27.1% in the term controls; only the late preterm group was signifi-
cantly different to the term controls (p = 0.018). Multivariable logistic regression analyses (a)
including all significant risk factors described above, and (b) including only family history of
atopy, showed results essentially the same as for univariate analysis for association of prematu-
rity and subsequent wheezing at both age groups.
The prevalence of wheeze-ever in children aged five years or older was 55.8%, 41.3%, 37.8%
and 27.7% respectively for the very preterm, moderate, late preterm and term groups with odds
ratios of 3.29 (95%CI 2.7, 4.1), 1.84 (95%CI 1.5, 2.3) and 1.58 (95%CI 1.3, 1.9) respectively
(Table 4). Slightly lower odds ratios were noted for recent wheeze (over the last 12 months),
doctor diagnosed asthma, use of inhaler medication including corticosteroids, and admission
to hospital over the previous 12 months for a respiratory illness. Family history of atopy
showed a prevalence of 18.4%, 21.8%, 24.2% and 22.7% for the very preterm, moderate, late
preterm and term groups respectively, with only the very preterm group being marginally dif-
ferent to the term controls (p = 0.046). Multivariable logistic regression analyses (a) including
all significant risk factors and (b) including only family history of atopy, showed results essen-
tially the same as for univariate analysis for association of prematurity and subsequent
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Fig 1. Diagram showing return rates of completed questionnaires in the Respiratory and Neurological
Outcomes of children born Preterm Study (RANOPS).
doi:10.1371/journal.pone.0155695.g001
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wheezing at both age groups. The wheezing rates of the term-born matched preterm-born
responders (both age groups) were similar to the results of all responders (Tables H and I in
S1 File).
The results of the sub-group analysis on only wheezing children identified the following sig-
nificant risk factors for preterm-born wheezy children aged less than five years: being delivered
by CS, IUGR, and current maternal smoking (Table C in S1 File). For the group aged five years
and older, the significant factors were delivery by CS and IUGR (Table D in S1 File). Rates of
family history of atopy were similar in the preterm- and term-born wheezing children on
inhaler treatment for both age’s groups (Table 5).
Table 1. Characteristics of responders <5 years of age according to gestational groups.
Very Preterm Moderate Preterm Late Preterm Full Term
N = 519 N = 486 N = 1,149 N = 1,403
Gestational age, weeks 29.7* 33.7* 35.7* 39.6*
(mean, 95%CI) (29.5,29.9) (33.6,33.7) (35.6,35.7) (39.6,39.7)
Birthweight, kg 1.45* 2.18* 2.64* 3.46*
(mean, 95%CI) (1.41, 1.50) (2.14, 2.22) (2.61, 2.66) (3.43, 3.49)
Male (%) 260 (50%) 275 (57%) 621 (54%) 743(53%)
WIMD rank (median) Range: 1–1909 898 929 934 997
Age, years 2.24 2.22 2.29 2.24
(mean, 95% CI) (2.16, 2.32) (2.14, 2.30) (2.24, 2.35) (2.19, 2.28)
Antenatal maternal smoking 72/511 (14.1%) 56/483 (11.6%) 136/1,143 (11.9%) 133/1,385 (9.6%)
Maternal age, years 30.5 30.5 30.1 30.3
(mean, 95%CI) (30.0, 31.1) (30.0, 31.0) (29.7, 30.5) (30.0, 30.6)
Mode of delivery (CS or not) 288 (55.5%)* 263 (54.1%)* 505 (44%)* 378 (26.9%)*
Missing data 33 (6.4%) 23 (4.7%) 60 (5.2%) 46 (3.3%)
IUGR 71(13.7%)* 64(13.2%)* 111(9.7%)* 97(6.9%)*
*Signiﬁcant difference (p<0.001) between groups.
doi:10.1371/journal.pone.0155695.t001
Table 2. Characteristics of responders’ ≥5 years of age according to gestational groups.
Very Preterm Moderate Preterm Late Preterm Full Term
N = 509 N = 466 N = 1,155 N = 1,462
Gestational age, weeks 29.8* 33.6* 35.6* 39.6*
(mean, 95%CI) (29.6, 30.0) (33.6, 33.7) (35.6, 35.7) (39.6, 39.7)
Birthweight, kg 1.45* 2.22* 2.64* 3.46*
(mean, 95%CI) (1.40, 1.49) (2.18, 2.26) (2.61, 2.67) (3.44, 3.49)
Male (%) 301 (59.1%) 260 (55.8%) 627 (54.2%) 775 (53%)
WIMD rank (median) Range: 1–1909 997* 936* 1,019* 1,110*
Age, years 7.1 7.1 7.3 7.2
(mean, 95%CI) (7.0, 7.3) (7.0, 7.3) (7.2, 7.4) (7.1, 7.3)
Antenatal maternal smoking 76/475 (16%) 67/432 (15.5%) 175/1,080 (16.2%) 184/1,343 (13.7%)
Maternal age, years 29.7 30.4 30.1 30.4
(mean, 95%CI) (29.2, 30.4) (29.8, 31.0) (29.7, 30.4) (30.1, 30.7)
Mode of delivery (CS or not) 269 (52.8%)* 229 (49.1%)* 439 (38%)* 344 (23.5%)*
Missing data 53 (10.4%) 41 (8.8%) 76 (6.6%) 162 (11.1%)
IUGR 77 (15.2%)* 39 (8.4%)* 116 (10.1%)* 95 (6.5%)*
*Signiﬁcant difference (p<0.001) between groups.
doi:10.1371/journal.pone.0155695.t002
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Preterm-born children who have a family history of atopy, had a greater risk for wheezing
than term-born children with a family history of atopy (OR 2.0, 95%CI 1.6, 2.4). However, pre-
term-born children without a family history of atopy also had similar greater risk of wheezing
than children born term without a family history of atopy (OR 1.9, 95%CI 1.7, 2.1) suggesting
that atopy does not play a part in the prematurity-associated wheeze (Fig 2). Similarly, pre-
term-born children with wheezing and a family history of atopy were treated with inhalers
more frequently than term-born children with wheeze and family history of atopy (OR 1.4,
95%CI 1.1, 1.8) which was similar to the comparison between preterm- and term-born children
with wheezing and no family history of atopy (OR 1.3, 95%CI 1.1, 1.6) (Fig 3).
Children with CLD, who were confined to the very preterm group, had lower birth weight
and gestational age than very preterm without CLD (Table E in S1 File). The CLD group had
greater rates of wheezing (71.7%), inhaler use (37.5%) and hospital admissions (17.1%)
Table 3. Childhood wheezing, family history, inhaler use and hospital admissions for all children less than 5 years-of-age compared by gestational
age (unadjusted OR).
Very Preterm Moderate Preterm Late Preterm Full Term
N = 502 N = 479 N = 1,130 N = 1,402
Wheeze-ever (%) 325 (64.7%) 266 (55.5%) 581 (51.4%) 571 (40.7%)
OR (95% CI) 2.7 (2.2, 3.3) 1.8 (1.5, 2.2) 1.5 (1.3, 1.8)
p-value <0.001 <0.001 <0.001
aOR (95% CI)# 2.6 (2.1, 3.3) 1.8 (1.4, 2.2) 1.5 (1.2, 1.7)
aOR (95% CI)^ 2.8 (2.2, 3.4) 1.9 (1.5, 2.3) 1.5 (1.3, 1.8)
Recent wheeze (%) 201 (40%) 160 (33.4%) 326 (28.8%) 261 (18.6%)
OR (95% CI) 2.9 (2.3, 5.7) 2.2 (1.7, 2.8) 1.8 (1.5, 2.1)
p-value <0.001 <0.001 <0.001
aOR (95% CI)# 2.9 (2.3, 3.6) 2.2 (1.7, 2.8) 1.7 (1.4,2.0)
aOR (95% CI)^ 3.0 (2.4, 3.8) 2.3 (1.8, 2.9) 1.7 (1.4,2.1)
Mild wheeze (%) 183 (36.5%) 146 (30.5%) 291 (25.8%) 238 (17%)
OR (95% CI) 2.8 (2.2, 3.5) 2.1 (1.7, 2.7) 1.7 (1.4, 2.1)
p-value <0.001 <0.001 <0.001
Severe wheeze (%) 18 (3.6%) 14 (2.9%) 35 (3.1%) 23 (1.6%)
OR (95% CI) 2.2 (1.2, 4.2) 1.8 (0.9, 3.5) 1.9 (1.1, 3.3)
p-value <0.05 0.1 <0.05
Family history of atopy (%) 131 (26.1%) 115 (24%) 355 (31.4%) 380 (27.1%)
OR (95% CI) 1.0 (0.8,1.2) 0.9 (0.7, 1.1) 1.2 (1.0, 1.5)
p-value 0.662 0.184 0.018
Any inhaler medication use (%) 167 (33.3%) 95 (19.8%) 222 (19.6%) 167 (11.9%)
OR (95% CI) 3.7 (2.9, 4.7) 1.8 (1.4, 2.4) 1.8 (1.5, 2.5)
p-value <0.001 <0.001 <0.001
Corticosteroid inhaler medication use (%) 52 (10.4%) 27 (5.6%) 76 (6.7%) 41 (2.9%)
OR (95% CI) 3.8 (2.5, 5.9) 2.0 (1.2, 3.3) 2.4 (1.6, 3.5)
p-value <0.001 0.007 <0.001
Hospital admission with breathing related problem (last 12 months) (%) 110 (21.9%) 58 (12.1%) 112 (9.9%) 77 (5.5%)
OR (95% CI) 4.8 (3.5, 6.6) 2.4 (1.7, 3.4) 1.9 (1.4, 2.6)
p-value <0.001 <0.001 <0.001
#Confounding factors–gender, FH of atopy, maternal smoking during pregnancy, CS, maternal history of asthma, breastfeeding at birth, current maternal
smoking, social status, ethnicity, and other family member smoking.
^adjusted for Family history of atopy only.
doi:10.1371/journal.pone.0155695.t003
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compared to term-born controls (Table 6). Children with CLD had significantly greater rates
of wheezing and inhaler use compared to the very preterm group without CLD. Children who
were born very preterm without CLD also had significantly greater rates of wheezing (58.2%),
Table 4. Childhood wheezing, family history, inhaler use and hospital admissions for all children 5 years-of-age and older compared by gesta-
tional age (unadjusted OR).
Very Preterm Moderate Preterm Late Preterm Full Term
N = 495 N = 450 N = 1,138 N = 1,456
Wheeze-ever (%) 276 (55.8%) 186 (41.3%) 430 (37.8%) 403 (27.7%)
OR (95% CI) 3.3 (2.7, 4.1) 1.8 (1.5, 2.3) 1.6 (1.3, 1.9)
p-value <0.001 <0.001 <0.001
aOR (95% CI)# 3.3 (2.7, 4.2) 1.8 (1.4, 2.2) 1.5 (1.3, 1.8)
aOR (95% CI)^ 3.5(2.8, 4.3) 1.9 (1.5, 2.4) 1.6 (1.3, 1.9)
Recent wheeze (%) 146 (29.5%) 92 (20.4%) 227 (19.9%) 217 (14.9%)
OR (95% CI) 2.4 (1.9, 3.0) 1.5 (1.1, 1.9) 1.4 (1.2, 1.7)
p-value <0.001 0.006 0.001
aOR (95% CI)# 2.4 (1.9, 3.1) 1.4 (1.0, 1.8) 1.3 (1.1, 1.7)
aOR (95% CI)^ 2.6 (2.0, 3.3) 1.5 (1.1, 2.0) 1.4 (1.1, 1.7)
Doctor diagnosis of asthma (%) 127 (25.7%) 78 (17.3%) 197 (17.3%) 182 (12.5%)
OR (95% CI) 2.4 (1.9, 3.1) 1.5 (1.1, 2.0) 1.5 (1.2, 1.8)
p-value <0.001 <0.01 <0.001
Family history of atopy (%) 91 (18.4%) 98 (21.8%) 275 (24.2%) 330 (22.7%)
OR (95% CI) 0.8 (0.6, 0.99) 1.0 (0.7, 1.2) 1.1 (0.9, 1.3)
p-value 0.046 0.694 0.370
Any inhaler medication use (%) 109 (22%) 66 (14.7%) 162 (14.2%) 159 (10.9%)
OR (95% CI) 2.3 (1.8, 3.0) 1.4 (1.0, 1.9) 1.4 (1.1, 1.7)
p-value <0.001 0.032 0.011
Corticosteroid inhaler medication use (%) 66 (13.3%) 36 (8%) 92 (8.1%) 92 (6.3%)
OR (95% CI) 2.3 (1.6, 3.2) 1.3 (0.9, 1.9) 1.3 (0.97, 1.8)
p-value <0.001 0.21 0.08
Hospital admission with breathing related problem (last 12 months) (%) 17 (3.4%) 16 (3.6%) 24 (2.1%) 23 (1.6%)
OR (95% CI) 2.2 (1.2, 4.2) 2.3 (1.2, 4.4) 1.3 (0.7, 2.3)
p-value 0.014 0.012 0.318
#Confounding factors–gender, FH of atopy, maternal smoking during pregnancy, CS, maternal history of asthma, breastfeeding at birth, current maternal
smoking, social status, ethnicity, and other family member smoking.
^adjusted for Family history of atopy only.
doi:10.1371/journal.pone.0155695.t004
Table 5. The influence of family history of atopy on wheezing children being treated with inhalers by
comparing preterm to term-born participants for both age groups.
Wheezing children on inhaler treatment (<5 years
old)
Preterm Term OR (95%
CI)











Wheezing children on inhaler treatment (≥5 years
old)
Preterm Term OR (95%
CI)
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inhaler use (25.6%) and hospital admissions (12%) when compared to term-born controls.
Family history of atopy was lower (p<0.05) between children with CLD (17.8%) and term-
born controls, and similar between very preterm children without CLD (23.1%) and term-born
controls (24.8%).
Fig 2. Prevalence of ever wheezing for the whole study population. Bars denote the percentage of
children having ever wheezed who have a family history of atopy (white bars) or not (black bars) and for both
gestational groups, preterm or term.
doi:10.1371/journal.pone.0155695.g002
Fig 3. Prevalence of inhaler treatment amongst wheezing children. Bars denote the percentage of
wheezy children being treated with inhalers who have a family history of atopy (white bars) or not (black bars)
and for both gestational groups, preterm or term.
doi:10.1371/journal.pone.0155695.g003
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Discussion
In this cross-sectional population-based cohort study, we explored the respiratory health out-
comes including symptoms, family history of atopy and inhaler treatment of children-born
preterm. Our results show that children (aged 1–10 years of age) born preterm have greater
respiratory symptoms, increased hospital admissions for respiratory related morbidity and
greater use of inhaler medication compared to term-born children. A gradient across the gesta-
tional age groups was observed with those born very preterm having the highest prevalence
rates. Importantly, we show that prematurity-associated wheeze appears to be independent of a
family history of atopy. Our results confirm that children born very preterm have significantly
higher prevalence of respiratory symptoms including wheezing during pre-school aged years as
previously reported [23, 24] but also during early school-aged years when compared to chil-
dren born full term. Prevalence of wheezing was increased in those with CLD and in those
without CLD when compared to the term population. For the whole population of preterm-
born children aged less than five years, the overall odds ratio for wheeze-ever was 1.8 (95% CI
1.6, 2.1), which is remarkably similar to those reported previously [7].
Our study also noted that preterm-born children were being treated with inhaler medication
(bronchodilators and corticosteroids) with greater frequency than term-born children. This
too showed a gradient effect with increasing drug usage with decreasing gestational age at
birth. Some studies have previously reported under treatment especially in those born very pre-
term with CLD [4, 9]. Whether the bronchodilators or corticosteroids are efficacious is specula-
tive and will require further studies. Other studies have identified an increased number of
prescriptions for inhaler medication for preterm-born children; however these are registry-
based studies that have been restrictive in their study population by identifying subjects by
diagnosis of asthma, thus the results are unsurprisingly associated with increased inhaler usage
and can not therefore comment on non-asthmatic forms of wheezing in childhood [25, 26]. Our
study specifically asked for inhaled drug usage, independently of any diagnostic labels given to
the child, thus is likely to be representative of the population of preterm-born children.
Our recent systematic review of studies evaluating efficacy of inhaled bronchodilator identi-
fied 21 studies but only one study from 1997, assessed longer-term response to terbutaline
Table 6. Childhood wheezing, family history, inhaler use and hospital admissions for very preterm born children with or without CLD compared to
full term (unadjusted OR).
CLD No CLD Full term
N = 152 N = 845 N = 2,858
Wheeze-ever (%) 109 (71.7%) 492 (58.2%) 974 (34.1%)
OR (95% CI) 4.9 (3.4, 7.0) 2.7 (2.3, 3.2)
p-value <0.001 <0.001
Family history of atopy (%) 27 (17.8%) 195 (23.1%) 710 (24.8%)
OR (95% CI) 0.65 (0.4, 0.999) 0.9 (0.8, 1.1)
p-value 0.049 N.S.
Any inhaler medication use (%) 57 (37.5%) 219 (25.95%) 326 (11.4%)
OR (95% CI) 4.7 (3.3, 6.6) 2.7 (2.2, 3.3)
p-value <0.001 <0.001
Hospital admission with breathing related problem (last 12 months) (%) 26 (17.1%) 101 (12%) 100 (3.5%)
OR (95% CI) 5.7 (3.6, 9.1) 3.7 (2.8, 5.0)
p-value <0.001 <0.001
Comparisons are between the very preterm group with CLD and without CLD groups against the term group.
doi:10.1371/journal.pone.0155695.t006
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showing an improvement [27]. The remaining studies only assessed responses to single doses
of inhaled bronchodilators generally showing positive responses [28]. Similarly studies assess-
ing the role of inhaled corticosteroids in this group of children are also limited [29, 30], and
both showed no significant improvement following treatment with corticosteroids. Thus treat-
ment needs to be evaluated in well-designed, adequately powered studies if we are to optimally
treat prematurity-associated wheezing and avoid untoward adverse effects of steroids, espe-
cially growth suppression [31].
A meta-analysis of>147,000 children from 31 European birth cohorts showed that children
born a lower gestational age or with accelerated infant weight gain have increased risk of child-
hood asthma [32]. The authors speculated that adaptation of the immune system in preterm
born children maybe a possible cause of this increased risk of asthma. However, they were not
able to assess the impact of atopy in prematurity-associated wheeze or treatment of the prema-
turity-associated wheezing. The increase in reported wheeze and other respiratory symptoms
in preterm-born children could potentially be associated with atopy as shown by Rosas-Salaza
et al [15], thus we explored if a family history of atopy was associated with the increased
reported respiratory symptoms in our population. The prevalence was largely the same
between the preterm and term groups at both ages. In addition, although the rates of wheezing
were increased in preterm-born subjects with a family history, there was a similar increase in
respiratory symptoms in subjects without a family history of atopy. Family history of atopy
was not significantly associated with respiratory symptoms when included in regression mod-
els. Thus the prematurity-associated wheeze appears not to be associated with a family history
of atopy.
In our study, the risk factors most strongly associated with wheeze-ever in preterm-born
children were the degree of prematurity with decreasing gestation associated with increasing
symptoms; mode of delivery and IUGR for both age groups; and current maternal smoking for
the less than 5-years of age group. Mode of delivery is likely to be associated with the degree of
prematurity but IUGR has been reported to be associated with increased respiratory disease in
preterm-born infants in the neonatal period [33] and in term-born children [34].
The mechanisms underlying wheezing disorders following preterm birth are unclear. Chil-
dren with atopic asthma have obstructive airflow secondary to airway inflammation and bron-
chial hyper-responsiveness, which is reversible with bronchodilators. However, preterm-born
children, or even those born early-term[13], with respiratory symptoms are likely to have alter-
native mechanisms, which may not respond similarly to current inhaled therapies. Prematurity
is clearly associated with delivery at an early stage of lung growth and subsequent lung develop-
ment may be disturbed [35]. Some studies have shown that maternal antibiotic use during
pregnancy increases the risk of asthma in early childhood suggesting a disturbance in the bacte-
rial ecology of the foetus may lead to asthma [36]. This may only be in relation to asthma and,
as prematurity-associated wheezing may have a different phenotype, different mechanisms
may be involved [37, 38]. Other possible mechanisms include early exposure to respiratory
viral infections, accelerated postnatal growth and swallowing dysfunction leading to recurrent
aspiration [32, 39, 40].
In survivors of CLD, the underlying lung pathology may resemble that of pulmonary
emphysema rather than asthma [41]. Our data shows that those with CLD had a greater rate of
wheezing when compared to those without CLD, as confirmed by our recent systematic review
[5]. Most studies, but without any adequate randomised control trials, have focused on
responses to individual doses of bronchodilators especially on children who had CLD in
infancy. Exhaled nitric oxide studies on children surviving CLD have not consistently shown
any increases in symptomatic children suggesting that eosinophilic dominant disease is
unlikely to explain the wheezing in preterm children [33]. Interestingly, individual reports
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suggest neutrophilic or oxidant injury may be continuing [42, 43]. However these are small
studies that need confirming and, more importantly, if these are primary or secondary effects
of prematurity and if they are modified by regular use of inhaled drugs.
Study Limitations
Our study has a few limitations. It is a cross-sectional study relying on parental reporting of
symptoms. Thus there is potential for recall bias. This may have affected the wheezing rates for
children over 5 years of age, which reports a lower rate of ever wheezing than children less than
5 years of age. However previous studies suggest that parental recall of acute illness correlates
well with medical records [44, 45]. We also included additional information from health data-
base to provide more comprehensive assessment and confirm diagnoses such as CLD from
doctor diagnosis. Ascertainment bias may have overestimated our results, as preterm-born
children are known to present more frequently for healthcare reviews thus may result in greater
diagnosis and possibly subsequent inhaler medication. However this is likely to be applicable
to both preterm and term-born groups and so unlikely to affect the overall results. There was
also a low response rate at 26.7%, even though previous studies had shown a good response
from families in Wales [46]. This may have resulted in recruitment bias and as shown by our
comparison between responders and non-responders, there is a difference in the social circum-
stances as responders had higher WIMD scores. We did account for this in our analysis and it
should be noted the response rate for preterm born children was 32%.
Conclusion
This large population-based study has confirmed and further quantified that preterm-born
children have increased prevalence of respiratory symptoms. Children born preterm with or
without a family history of atopy had a higher prevalence of wheezing and were more fre-
quently on inhaler treatment when compared to term-born children. Prematurity-associated
wheeze is likely to be a separate entity to the wheezing observed in term-born children espe-
cially as delivery occurs at an earlier stage of lung growth, which may affect subsequent lung
development. It is vital that we identify optimal treatment for this significant group of children
by identifying the underlying mechanisms responsible for the airway symptoms and obstruc-
tion together with adequately powered randomised controlled trials.
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